Skip to content

Financials

Find our consolidated key figures and our financial calendar below, or go directly to our financial reports and SEC filings

Corporate Calendar 2027

DateDetails
February 24, 2027Full-year results 2026
March 25, 2027Annual report 2026
April 27, 2027Annual General Shareholders’ Meeting
May 3, 2027First quarter results 2027
August 4, 2027Half-year results 2027
November 3, 2027Third quarter results 2027

Financial Reports

Annual Report? Half year report? All financial reports, right here!

Key Financials

Consolidated Key Figures

(thousands of €, if not stated otherwise)Nine months ended September 30, 2026Nine months ended September 30, 2025Year ended December 31, 2025
Income statement
Supply revenues17.72629.33229.924
Collaboration revenues8.443182.0941.082.324
Total net revenues26.169211.4261.112.248
Cost of sales(17.621)(29.281)(29.736)
R&D expenses(82.498)(351.909)(459.421)
S&M, G&A expenses(76.601)(109.017)(153.433)
Impairment of the cell therapy activities–(204.753)(228.112)
Other operating income2.16521.37453.493
Operating profit/loss (-)(148.386)(462.160)295.039
Net financial results156.173(20.124)5.832
Taxes(245)19.28718.621
Net profit/loss (-) from continuing operations7.542(462.997)319.492
Net profit from discontinued operations, net of tax6.3881.7351.392
Net profit/loss (-)13.930(461.262)320.884
Balance sheet
Cash and cash equivalents94.65564.45887.868
Financial investments2.088.4842.985.6562.910.180
R&D incentives receivables126.347149.339157.870
Assets3.294.5683.511.9143.406.518
Shareholders’ equity3.232.7622.446.9633.235.868
Deferred income33896.43132
Other liabilities61.773168.520170.618
CASH FLOW
Operational cash burn (*)(97.185)(145.129)(189.141)
Cash flow used in operating activities(152.143)(209.995)(257.456)
Cash flow generated from investing activities195.328216.191288.814
Cash flow used in financing activities(42.919)(2.868)(3.273)
Increase in cash and cash equivalents2663.32828.085
Effect of currency exchange rate fluctuation on cash and cash equivalents6.521(3.109)(4.456)
Cash and cash equivalents at the end of the period94.65564.45887.868
Financial investments at the end of the period2.088.4842.985.6562.910.180
Total financial investments and cash and cash equivalents at the end of the period2.183.1393.050.1142.998.048
FINANCIAL RATIOS
Number of shares issued at the end of the period65.897.07165.897.07165.897.071
Basic and diluted earnings/loss (-) per share0,21(7,00)4,87
Share price at the end of the period (in €)26,4229,1628,00

(*)The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.
the net proceeds, if any, from share capital and share premium increases, and the cash used for the purchase of own shares, included in the net cash flows generated from/used in (-) financing activities
the net proceeds or cash used, if any, related to the acquisition or disposal of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities

SEC Filings

SEC filings are the official documents we submit to the U.S. Securities and Exchange Commission (SEC). They contain financial and non-financial information essential for regulatory compliance and transparency.